Shanghai MicroPort Endovascular MedTech Co., Ltd.

SHSE:688016 Rapporto sulle azioni

Cap. di mercato: CN¥11.9b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Shanghai MicroPort Endovascular MedTech Crescita futura

Future criteri di controllo 5/6

Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 24% and 25% per annum respectively. EPS is expected to grow by 21.1% per annum. Return on equity is forecast to be 18.1% in 3 years.

Informazioni chiave

24.0%

Tasso di crescita degli utili

21.1%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili22.5%
Tasso di crescita dei ricavi25.0%
Rendimento futuro del capitale proprio18.1%
Copertura analitica

Good

Ultimo aggiornamento03 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Aug 15
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

Jun 29
Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Apr 29
These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Apr 09
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Mar 25
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Previsioni di crescita degli utili e dei ricavi

SHSE:688016 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20262,5401,0715409777
12/31/20251,94680243976910
12/31/20241,53663543161110
3/31/20241,260552458651N/A
12/31/20231,187492368558N/A
9/30/20231,121444166398N/A
6/30/20231,05942122369N/A
3/31/2023924358-10308N/A
12/31/202289735740334N/A
9/30/2022839367133340N/A
6/30/2022781346276362N/A
3/31/2022745338242337N/A
12/31/2021685316211300N/A
9/30/2021652302248299N/A
6/30/2021618279255291N/A
3/31/2021569257239269N/A
12/31/2020470215191217N/A
9/30/2020414192148174N/A
6/30/2020377177142166N/A
3/31/2020341156133154N/A
12/31/2019334142122143N/A
9/30/2019306127117138N/A
6/30/201928211584117N/A
3/31/201925710390118N/A
12/31/20182319182107N/A
12/31/201716563N/A69N/A
12/31/201612541N/A30N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: 688016's forecast earnings growth (24% per year) is above the savings rate (2.9%).

Guadagni vs Mercato: 688016's earnings (24% per year) are forecast to grow faster than the CN market (21.9% per year).

Guadagni ad alta crescita: 688016's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: 688016's revenue (25% per year) is forecast to grow faster than the CN market (13.4% per year).

Ricavi ad alta crescita: 688016's revenue (25% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: 688016's Return on Equity is forecast to be low in 3 years time (18.1%).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y